Fig. 6. SHP-2 ablation induces lasting antitumor properties in monocytes.

a, Tumor size in naïve WT mice subcutaneously injected with MC17-51 tumor cells with or without injection with CD45⁺CD11b⁺Ly6C^hiLy6G⁻ monocytes or CD45⁺CD11b⁺Ly6C⁻Ly6G⁺ neutrophils isolated from the bone marrow of Shp2^f/fLysM^Cre mice on day 9 post inoculation of MC17-51 tumors. b, Tumor weight on day 15 in mice as in a. Results show mean + s.d. Results are from one of two experiments with n = 10 mice per group. *P = 0.0104–0.0387, **P = 0.0033, ANOVA. c,d, The indicated subsets of Lin- myeloid progenitors (c) and mature CD45⁺CD11b⁺ myeloid cells and the subsets of CD45⁺CD11b⁺Ly6C^hiLy6G⁻ monocytes (CD11b⁺Ly6C⁺) and CD45⁺CD11b⁺Ly6C⁻Ly6G⁺ neutrophils (CD11b⁺Ly6C⁺) were assessed in the bone marrow of Shp2^f/f and Shp2^f/fLysM^Cre tumor-bearing mice on day 9 before collection of monocytes or neutrophils from Shp2^f/fLysM^Cre tumor-bearing mice for transfer into the new hosts. Results are from one of three separate experiments with n = 5 mice per group.